Loading organizations...
§ Private Profile · Cincinnati, OH, USA
Biotech startup developing small-molecule therapies targeting IRAK1/4 signaling for hematologic malignancies like AML and MDS.
Kurome Therapeutics, based in Cincinnati, Ohio, develops small-molecule therapies targeting cancer's immune evasion mechanisms, specifically IRAK1/4 signaling pathways in cancers like refractory/relapsed AML and high-risk MDS. The company has synthesized over 1,600 derivatives of an initial compound, leading to KME-0584, which is on track for clinical trials in 2024 for patients with limited treatment options, following an FDA IND opening. Kurome secured $15 million in Series A financing in 2021, building on prior seed funding, with investors including Medicxi and CincyTech. Its drug development efforts are led by President, CEO, and CSO Jan Rosenbaum, with key research contributions from Daniel Starczynowski and early collaboration from Craig Thomas. Kurome Therapeutics was launched in 2020. Its business model centers on biotech startup funded through venture capital, licenses technology from Cincinnati Children’s and advances drugs toward clinical trials.
Kurome Therapeutics has raised $15.0M across 1 funding round.
Kurome Therapeutics has raised $15.0M in total across 1 funding round.
Kurome Therapeutics has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Series A in June 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 10, 2021 | $15M Series A | Daniel Heller, Aaron Kantoff | CincyTech USA | Announced |
Kurome Therapeutics has raised $15.0M in total across 1 funding round.
Kurome Therapeutics's investors include Daniel Heller, Aaron Kantoff, CincyTech.